Skip to main content

Table 2 Relationship between immunochemical features and disease status

From: Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature

Target expression Bladder cancer, % Benign, % p-value Target expression Bladder cancer, % Benign, % p-value
VEGFA     APOE    
1 47 (28.7%) 12 (16.2%) 0.115 1 30 (15.5%) 36 (50.7%) <0.0001
2     2 44 (22.8%) 22 (31.0%)  
3     3 54 (28.0%) 12 (16.9%)  
4     4 65 (33.7%) 1 (1.4%)  
MMP9     SERPINA1    
1 14 (7.7%) 50 (67.6%) <0.0001 1 35 (18.8%) 30 (40.5%) <0.0001
2 47 (25.8%) 17 (23.0%)   2 40 (21.5%) 25 (33.8%)  
3 60 (33.0%) 4 (5.4%)   3 49 (26.3%) 16 (21.6%)  
4 61 (33.5%) 3 (4.1%)   4 62 (33.3%) 3 (4.1%)  
MMP10     SDC1    
1 37 (20.2%) 27 (36.5%) <0.0001 1 27 (14.6%) 36 (51.4%) <0.0001
2 36 (19.7%) 28 (37.8%)   2 35 (18.9%) 29 (41.4%)  
3 46 (25.1%) 18 (24.3%)   3 60 (32.4%) 4 (5.7%)  
4 64 (35.0%) 1 (1.4%)   4 63 (34.1%) 1 (1.4%)  
SERPINE1     ANG    
1 47 (25.7%) 16 (22.2%) <0.0001 1 4 (2.1%) 62 (86.1%) <0.0001
2 31 (16.9%) 33 (45.8%)   2 56 (29.0%) 10 (13.9%)  
3 46 (25.1%) 18 (25.0%)   3 66 (34.2%) 0 (0%)  
4 59 (32.2%) 5 (6.9%)   4 67 (34.7%) 0 (0%)  
IL8        
1 56 (28.6%) 10 (24.3%) <0.0001     
2 43 (21.9%) 24 (34.3%)      
3 36 (18.4%) 30 (32.9%)      
4 61 (31.1%) 6 (8.6%)      
CA9        
1 35 (17.9%) 31 (44.3%) <0.0001     
2 49 (25.0%) 18 (25.7%)      
3 48 (24.5%) 18 (25.7%)      
4 64 (32.7%) 3 (4.3%)